NCT00971113

Brief Summary

The human intestinal microflora is characterized as a complex and dynamic microbial ecosystem with crucial contribution to our nutrition and welfare. Health-promoting genera such as Bifidobacterium spp. and Lactobacillus spp. play a key role in digestion of nutrients, production of short chain fatty acids and vitamins, inhibition of harmful bacteria, immunostimulation, reduction of blood cholesterol and ammonia levels and restoration of normal flora after antibiotic therapy. Proteolytic species such as toxin-producing clostridia and toxigenic E. coli are considered as potential pathogens with detrimental effects to human host. Recently, part of novel food research is directing towards the concept of prebiotics e.g. food ingredients that are not hydrolyzed by the human gastrointestinal tract and beneficially affect the host by selectively stimulating the growth and/or activity of one or limited number of bacteria in the colon that can improve host health. Fructo-oligosaccharides and inulin, are considered as the most extensively studied and well-established prebiotics. In vitro and in vivo data suggest the bifidogenic effect of inulin and oligofructose, which can be attributed to their selective fermentation by Bifidobacterium species. Due to their documented prebiotic properties, both inulin and FOS are increasingly applied in novel food product development through the fortification of commonly ingested foodstuffs. The aim of this study is to evaluate the in vivo prebiotic effect of a functional food containing short-chain fructo-oligosaccharides (sc-FOS) and Sideritis euboea extract on the faecal microflora composition of healthy human volunteers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2007

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2007

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2007

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

September 2, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 3, 2009

Completed
Last Updated

September 3, 2009

Status Verified

September 1, 2009

Enrollment Period

5 months

First QC Date

September 2, 2009

Last Update Submit

September 2, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • to evaluate the in vivo prebiotic effect of an jelly containing sc-FOS and Sideritis euboea extract on the faecal microflora composition and to evaluate the effect of jelly containing sc-FOS and Sideritis euboea extract on gastrointestinal symptoms

    30d intervention and 2 wks follow-up

Study Arms (2)

sc-FOS+Sideritis euboea group

EXPERIMENTAL

Jelly supplemented with short chain fructooligosaccharides and Sideritis euboea extract

Dietary Supplement: sc-FOS and Sideritis euboea extract

placebo group

PLACEBO COMPARATOR

Jelly without short-chain fructooligosaccharides and Sideritis euboea

Dietary Supplement: sc-FOS and Sideritis euboea extract

Interventions

dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days placebo food: jelly with no sc-FOS and Sideritis euboea

placebo groupsc-FOS+Sideritis euboea group

Eligibility Criteria

Age20 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy adult subjects

You may not qualify if:

  • History of gastrointestinal disease
  • Chronic diseases (i.e.,diabetes,cardiovascular diseases, hyperlipidemia, autoimmune disorders)
  • History of epileptic seizures
  • Extreme dietary behaviours
  • Consumption of antibiotics and other medication 2 months prior and during the investigation period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Harokopio University

Kallithea, Attica, 17671, Greece

Location

Study Officials

  • Adamantini Kyriacou, Ass. Professor

    Harokopio University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 2, 2009

First Posted

September 3, 2009

Study Start

April 1, 2007

Primary Completion

September 1, 2007

Study Completion

December 1, 2007

Last Updated

September 3, 2009

Record last verified: 2009-09

Locations